Browsing Tag
NCCN
2 posts
Corcept Therapeutics (NASDAQ: CORT) climbs 7% as Lifyorli launch and analyst upgrades drive cortisol re-rating
Corcept turned a stress hormone into an ovarian cancer drug. Lifyorli is launching fast and analysts are chasing, but a premium multiple prices in a lot.
Lilly’s Phase 3 EMBER-3 trial results set to shake up breast cancer treatment landscape
Eli Lilly and Company (NYSE: LLY) announced it will present data from its Phase 3 EMBER-3 trial for…